{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=49",
    "query": {
      "intervention": "cohort 1",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 8005,
    "total_pages": 801,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=50&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=48&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T20:21:42.723Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02637687",
      "title": "A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors Harboring NTRK Fusion"
      ],
      "interventions": [
        {
          "name": "Larotrectinib (Vitrakvi, BAY2757556)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 154,
      "start_date": "2015-12-16",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637687"
    },
    {
      "nct_id": "NCT02614612",
      "title": "Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft-versus-host Disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Itacitinib (200 mg)",
          "type": "DRUG"
        },
        {
          "name": "Itacitinib (300 mg)",
          "type": "DRUG"
        },
        {
          "name": "prednisone or methylprednisolone (corticosteroids)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2015-12",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2019-03-08",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 23,
      "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614612"
    },
    {
      "nct_id": "NCT07104565",
      "title": "Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "INCA000585",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2025-12-29",
      "completion_date": "2028-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 9,
      "location_summary": "Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 6 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Cooper City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07104565"
    },
    {
      "nct_id": "NCT06254807",
      "title": "CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive"
      ],
      "interventions": [
        {
          "name": "CT-0525",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carisma Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2024-01-08",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254807"
    },
    {
      "nct_id": "NCT05394064",
      "title": "A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AMN",
        "AMN Gene Mutation",
        "X-ALD"
      ],
      "interventions": [
        {
          "name": "SBT101 Treatment",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "SwanBio Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2022-11-17",
      "completion_date": "2025-08-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05394064"
    },
    {
      "nct_id": "NCT02567799",
      "title": "BIO 300 Non-Small Cell Lung Cancer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "BIO 300 Oral Suspension",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Humanetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-11",
      "completion_date": "2020-09",
      "has_results": true,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Detroit, Michigan • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02567799"
    },
    {
      "nct_id": "NCT01100021",
      "title": "Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Erectile Dysfunction"
      ],
      "interventions": [
        {
          "name": "Tamsulosin and avanafil",
          "type": "DRUG"
        },
        {
          "name": "Doxazosin and avanafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VIVUS LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "40 Years to 65 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2010-02",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2011-01-07",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100021"
    },
    {
      "nct_id": "NCT03872206",
      "title": "Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers Associated With Mesothelin Expression"
      ],
      "interventions": [
        {
          "name": "HPN536 Fixed IV 6 to 560 ng/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HPN536 1 Prime Step IV 600-1200 ng/kg Target",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2 Prime Step IV 900-14000 ng/kg Target",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2019-04-16",
      "completion_date": "2023-01-04",
      "has_results": false,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03872206"
    },
    {
      "nct_id": "NCT04487106",
      "title": "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelomonocytic Leukemia",
        "Recurrent Myelodysplastic Syndrome",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myelomonocytic Leukemia",
        "Refractory Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2020-07-21",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04487106"
    },
    {
      "nct_id": "NCT03462004",
      "title": "Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Virus Disease"
      ],
      "interventions": [
        {
          "name": "HPIV3/ΔHNF/EbovZ GP vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 15,
      "start_date": "2018-03-05",
      "completion_date": "2019-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-19T20:21:42.723Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03462004"
    }
  ]
}